In search of a selective therapy of viral infections
- PMID: 19852983
- DOI: 10.1016/j.antiviral.2009.10.005
In search of a selective therapy of viral infections
Abstract
This article is meant as an introductory chapter to the special issue of Antiviral Research on "Twenty-five years of antiretroviral drug development: progress and prospects", commemorating the first description of azidothymidine (AZT) as an antiretroviral agent. This has prompted me to highlight some of the hallmarks that played an important role in my own search of a selective therapy of viral infections: i.e., the induction of interferon by double-stranded RNA [such as poly(I).poly(C)], allowing the cloning and expression of beta-interferon; the discovery of the reverse transcriptase (RT) (and HIV as a retrovirus depending for its replication on RT), allowing the identification and development of a wide variety of RT inhibitors, nowadays used for the treatment of AIDS; the specificity of herpesvirus inhibitors such as acyclovir and BVDU, in the treatment of HSV and VZV infections; the role of acyclic nucleoside phosphonates (tenofovir, adefovir and cidofovir) in the treatment of HIV, HBV and DNA virus infections; and that of the NNRTIs (leading from TIBO to rilpivirine) as an essential part of the current anti-HIV drug cocktails. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, vol. 85, issue 1, 2010.
Copyright 2010. Published by Elsevier B.V.
Similar articles
-
A 40-year journey in search of selective antiviral chemotherapy.Annu Rev Pharmacol Toxicol. 2011;51:1-24. doi: 10.1146/annurev-pharmtox-010510-100228. Annu Rev Pharmacol Toxicol. 2011. PMID: 20809796 Review.
-
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.Antiviral Res. 2010 Jan;85(1):39-58. doi: 10.1016/j.antiviral.2009.09.014. Epub 2009 Nov 1. Antiviral Res. 2010. PMID: 19887088 Review.
-
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).Antiviral Res. 2010 Jan;85(1):75-90. doi: 10.1016/j.antiviral.2009.09.008. Epub 2009 Sep 23. Antiviral Res. 2010. PMID: 19781578 Review.
-
Antiviral drug discovery and development: where chemistry meets with biomedicine.Antiviral Res. 2005 Aug;67(2):56-75. doi: 10.1016/j.antiviral.2005.05.001. Antiviral Res. 2005. PMID: 16046240 Review.
-
Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.Antiviral Res. 2010 Jan;85(1):101-18. doi: 10.1016/j.antiviral.2009.11.004. Epub 2009 Nov 17. Antiviral Res. 2010. PMID: 19925830 Review.
Cited by
-
Mitotherapy inhibits against tenofovir induced nephrotoxicity on rat renal proximal tubular cells.Biochem Biophys Rep. 2024 Feb 26;38:101669. doi: 10.1016/j.bbrep.2024.101669. eCollection 2024 Jul. Biochem Biophys Rep. 2024. PMID: 38434141 Free PMC article.
-
Computational Studies of Benzoxazinone Derivatives as Antiviral Agents against Herpes Virus Type 1 Protease.Molecules. 2015 Jun 10;20(6):10689-704. doi: 10.3390/molecules200610689. Molecules. 2015. PMID: 26065834 Free PMC article.
-
Adenine: an important drug scaffold for the design of antiviral agents.Acta Pharm Sin B. 2015 Sep;5(5):431-41. doi: 10.1016/j.apsb.2015.07.002. Epub 2015 Sep 2. Acta Pharm Sin B. 2015. PMID: 26579473 Free PMC article. Review.
-
Inhibition of Chikungunya virus by an adenosine analog targeting the SAM-dependent nsP1 methyltransferase.FEBS Lett. 2020 Feb;594(4):678-694. doi: 10.1002/1873-3468.13642. Epub 2019 Nov 2. FEBS Lett. 2020. PMID: 31623018 Free PMC article.
-
2,4-Dioxo-1-(prop-2-yn-yl)-1,2,3,4-tetra-hydro-pyrimidine-5-carbaldehyde.Acta Crystallogr Sect E Struct Rep Online. 2011 Sep 1;67(Pt 9):o2350. doi: 10.1107/S1600536811032272. Epub 2011 Aug 17. Acta Crystallogr Sect E Struct Rep Online. 2011. PMID: 22058966 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical